ClinicalTrials.gg
CompletedNCT01106417Updated Jun 29, 2020

Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion

A Phase 1/2 interventional study of NeoFuse and MasterGraft Granules in Cervical Degenerative Disc Disease, Degenerative Spondylolisthesis and Spinal Stenosis, sponsored by Mesoblast, Ltd.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by Mesoblast, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and preliminary efficacy of NeoFuse in subjects with a diagnosis of degenerative disc disease (DDD) at 2 or more adjacent cervical vertebral levels between C3-C4 to C7-T1. All subjects in this study will undergo 2 or 3 level anterior cervical discectomy and fusion with Anterior Cervical Plate Fixation.

Read the detailed description

This is a prospective, multicenter, randomized, single-blinded, controlled study evaluating safety and preliminary efficacy of immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Matrix in a commercially available PEEK cervical Spacer compared to an active control in subjects undergoing 2 or 3 level anterior cervical discectomy and fusion with anterior cervical plate fixation.

After the screening and surgical visits, each subject will be evaluated clinically and radiographically within 3 days and 30 days after surgery, and at 3, 6, 12, and 24 months after surgery.

Subjects will be evaluated at the same time points for safety.

02

Conditions studied

  • Cervical Degenerative Disc Disease
  • Degenerative Spondylolisthesis
  • Spinal Stenosis

Browse trials for

Keywords

  • Cervical Degenerative Disc Disease
  • Degenerative Spondylolisthesis
  • Spinal Stenosis
  • Stem cells
  • Adult Stem Cells
  • Anterior cervical discectomy and Fusion (ACDF)
  • Anterior Cervical Plate Fixation
03

In context

Spinal Stenosis

460 studies on the registry are indexed under Spinal Stenosis; 107 are open to participants now.

This study's enrollment of 12 is below the median of 80 across 282 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

Mesoblast, Ltd. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or females between 18 and 70 years of age, inclusive.
  2. Has the ability to understand the requirements of the study, to provide written , and to comply with the study protocol.
  3. Has the ability to understand and provide written authorization for the use and disclosure of personal health information (PHI).
  4. Has a documented symptomatic diagnosis of DDD at C3-C4 to C7-T1.
  5. Has symptomatic radiculopathy and/or myelopathy correlating to radiographic findings of duration of 6 weeks or greater that had failed to respond to non-operative management
  6. Is a candidate for anterior cervical discectomy and fusion in two or three adjacent cervical interbody levels between C3-C4 to C7-T1
  7. Has a stable screening (ECG), as determined by the investigator that would not preclude surgery.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or nursing, or women planning to become pregnant during the first year (12 months) following surgery.
  2. Has a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  3. Has at the time of surgery a systemic or local infection at the site of proposed surgery.
  4. Has or is undergoing revision of a prior fusion surgery at any involved level.
  5. Requires ACDF at only one cervical interbody level or more than 3 adjacent cervical interbody levels.
  6. Requires ACDF without the use of an anterior cervical plating system.
  7. Has osteoporosis as defined by a DEXA T score of ≤ -3.0 or a history of fragility fractures or other significant bone disease contraindicating the use of spinal instrumentation.
  8. Has a documented medical history or radiographic evidence of a metabolic bone disease or other condition which would negatively impact the bone healing process.
  9. Has a positive screen for (HIV) antibodies.
  10. Has had treatment with any therapy or device within 6 months of study surgery and/or plans to participate in any other allogeneic stem cell/progenitor cell therapy trial during the 2-year follow-up period.
  11. Has been a recipient of prior stem cell/progenitor cell therapy for spinal fusion surgery.
  12. Has 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody specificities to donor HLA antigens.
  13. Is transient or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an inpatient substance abuse program.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    NeoFuse

    Anterior Cervical Discectomy and Fusion with NeoFuse. NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved. The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level.

    Biological: NeoFuse

  • Active comparator
    MasterGraft Granules

    Anterior Cervical Discectomy and Fusion with MasterGraft Granules MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process

    Device: MasterGraft Granules

Interventions

  • BiologicalRexlemestrocel-lStudies of Rexlemestrocel-lRexlemestrocel-l pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single Dose NeoFuse Surgical Implantation

    Also known as: Anterior Cervical Discectomy and Fusion with NeoFuse, Cervical Spinal Fusion, Adult Stem Cells

  • DeviceMasterGraft Granules

    Single Dose MaterGraft Granules Surgical Implantation

    Also known as: Anterior Cervical Discectomy and Fusion with Granules, Cervical Spinal Fusion, Active Control

06

What researchers measure

Primary outcomes

  1. Safety of NeoFuse

    To determine the safety of NeoFuse using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and and immunology).

    Time frame: 2 years

Secondary outcomes

  1. Fusion success with NeoFuse

    To evaluate the fusion success with NeoFuse compared to an active control using CT scans and x-ray of the involved cervical spine levels and assess the change in outcomes (NDI, SF-36, Zung Depression Questionnaire, and WPAI.

    Time frame: 1 year

07

Study locations

2 sites
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of May 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2010
First posted
Apr 19, 2010
Start
Jun 2010
Primary completionActual
May 2012
CompletionActual
Mar 2013
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01106417
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
Apr 19, 2010
Start date
Jun 2010
Primary completion
May 2012
Completion
Mar 2013
Last update
Jun 29, 2020

Study contacts

Roger Brown
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rexlemestrocel-l

Start the discussion